Chiara Corti
@ccortimd
MD, Fellow @DanaFarber @Harvard • Oncologist from @IEOufficiale @LaStatale • Editor @PLOSDigiHealth • @scuolapolitiche 2020 • Epistemic diversity enthusiast.
ID: 287134352
https://linktr.ee/ccortimd 24-04-2011 11:32:17
5,5K Tweet
2,2K Takipçi
898 Takip Edilen
Don't miss this review on #ArtificialIntelligence as treatment support in #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40882392/ Giacomo de Micheli Chiara Corti Sara Tolaney G Curigliano MD PhD Sibylle Loibl Paolo Tarantino #JosePabloLeone
Great experience participating in the U.S. FDA / ASCO Fellows’ Day Workshop. Engaging case-based discussions on approval pathways and the regulatory decision process. Thanks to Tatiana Prowell, MD and the organizers for such an interactive and insightful workshop. Dana-Farber’s Breast Oncology Center
📣Another step forward for #precision_immunotherapy in breast cancer! 🚀Just out in npj Journals Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in #TNBC. 📌rdcu.be/eIKAH
Our team is deeply grateful for this funding, which will support sequencing and computational work aimed at addressing urgent questions in a patient population already at high risk of relapse. Jorge Gómez Tejeda Zañudo Daniel Abravanel, MD/PhD Sara Tolaney
Thanks, Dr. Angie DeMichele, MD, MSCE, FASCO , for acknowledging our study. I love how you approach data discussions with a pragmatic, RW perspective and a focus on what matters most clinically—such as disease biology and patient outcomes after recurrence here. 🙏🏻 #ESMO25
Joined Harold J. Burstein, MD, PhD, FASCO contest during #ESMO25 ESMO - Eur. Oncology review: proposed algorithm for first- and second-line #EndocrineTherapy in ER-positive/HER2-negative metastatic #BreastCancer OncoAlert